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Background: Falciparum malaria increases the risk for bacteraemia, whereas the relationship between vivax malaria
and bacteraemia is not clear. Data from a prospective fever surveillance study in Kolkata, India were reanalysed for
the potential association between Plasmodium vivax malaria and bacteraemia.
Methods: Patients of all ages presenting with fever of three days or more to a project health outpost were invited
to participate. A blood film and blood culture was performed on presentation. Treatment and referral were
provided according to national guidelines. The case fraction and incidence of malaria, bacteraemia, and co-infection
were calculated.
Results: 3,371 participants were enrolled during a one-year study period, of whom 93/3,371 (2.8%) had malaria
(89/93 [95.7%] Plasmodium vivax) and 256 (7.6%) bacteraemia. There were 154 malaria, 423 bacteraemia and 10
P. vivax-bacteremia coinfection episodes per 100,000/year. Among the malaria-bacteraemia co-infections, all were
vivax malaria and 5/6 (83%) bacteria isolated were Gram-negative (one S. Typhi, one S. Paratyphi A, three other
Gram-negative). Bacteraemia occurred in 6/89 (6.7% [95%CI: 3.1-13.9%]) of P. vivax cases versus 250/3,278
(7.6% [95% CI: 6.7-8.6%]) without Plasmodium infection (p=0.76).
Conclusions: While an increased risk was not demonstrated, concomitant bacteraemia occurs frequently in vivax
malaria in an area with a high background incidence of bacteraemia, and should be considered in cases of vivax
malaria with severe manifestations.
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The association between Plasmodium falciparum infection
and bacteraemia is well documented [1]. A report from
Nigeria suggested the association between invasive
salmonellosis and falciparum malaria in children [2].
It was then shown that young Gambian children with
invasive non-typhoidal Salmonella infection were more
anaemic and more likely to have evidence of recent mal-
aria than were children of the same age with other forms
of septicaemia [3]. Studies in Kenya showed that an acute
episode of falciparum malaria predisposes to bacteraemia
and that the latter contributes to the clinical picture of
severe malaria [4]. The association between non-typhoidal* Correspondence: deen.jacqueline@gmail.com
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distribution, and reproduction in any mediumSalmonella bacteraemia and severe anaemia has also been
found in Malawi [5,6]. A recent study in Kenya has
provided the strongest evidence to date of P. falciparum
infection increasing the risk for bacteraemia, particularly
for Gram-negative invasive infections [7]. Strategies that
control falciparum malaria reduce child mortality to a
greater extent than can be attributed to malaria alone
[8,9], likely through its mitigation of bacterial disease.
In contrast to falciparum malaria, the relationship
between vivax malaria and bacteraemia has been less
explored. The rate of concomitant bacteraemia in severe
Plasmodium vivax malaria is not known, nor the extent
to which concomitant bacterial infections contributes to
the manifestations of severe vivax disease. Although there
are reports of uncomplicated and severe vivax malaria
with concurrent bacteraemia [10-12], recent series of severe
vivax malaria cases with sepsis-like syndromes, includingentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tematic collection of pre-antibiotic blood cultures [13-15].
Importantly, there are increasing reports of P. vivax with
severe clinical syndromes [16]. Data from a prospective
fever surveillance study was reanalysed to assess the
frequency of concomitant bacteraemia in P. vivax-infected
patients presenting for primary care treatment of fever and
the possible association between these two conditions.
Methods
Study population and procedures
The study population and procedures have been previously
described in detail [17]. Briefly, the site was in Kolkata,
India and consisted of wards 29 and 30, which are legally
registered urban slum areas (bustees). The area is densely
populated with narrow streets, little space between houses,
intermittent piped water supply and inadequate sanitation
facilities. A 2004 study census recorded a population of
60,452, of whom 15,980 were two months to 14 years of
age [17]. Prospective fever surveillance was conducted from
January-December 2004 in preparation for a large typhoid
fever vaccine effectiveness trial [18]. Five project health
outposts set-up in the study area were open daily from
08:00–20:00 hours. Two project health outposts in the
city’s infectious diseases hospital and children’s referral
hospital were open 24 hours a day. Each outpost, operated
by a physician and five assistants, offered free treatment
according to national guidelines or referral with free trans-
port to hospital when required. From the study population,
all patients with fever for three days or more, irrespective of
age, were invited to participate.
From each participant, a drop of blood was used for a
thin blood film and stained with Leishman’s stain. At
least 100 high-power thin film microscopic fields were
examined to exclude the diagnosis of malaria. Plasmodium
species were identified on the thin film and confirmed by a
senior malariologist. Approximately 5–8 ml of blood from
adults and 3–5 ml from children were collected and used
to inoculate BACTEC-Plus Aerobic® and BACTEC-Peds
Plus® culture vials (Becton Dickinson), respectively. Inocu-
lated Bactec bottles were incubated at 37°C for seven days
with subcultures made on MacConkey agar (Difco) during
the 1st, 2nd, 4th, and 7th days of incubation. Colonies
detected on the plates were checked by Gram staining and
other biochemical tests following standard procedures.
Identification of Salmonella enterica serotype Typhi and
Paratyphi strains was confirmed by slide and tube agglutin-
ation using polyvalent and monovalent factor antisera
(Becton Dickinson) for O and H antigens. Salmonella
isolates were preserved in glycerol stock at −70°C, and their
identities verified at a reference laboratory (University
of Oxford-Wellcome Trust Clinical Research Unit, Ho
Chi Minh City, Vietnam). Other Gram-negative and
Gram-positive bacteria were not identified further.Data management, definitions and analysis
Standard case report forms were used to record medical
history, physical examination findings, laboratory results
and clinical management. Data were double-entered into
custom-made data entry programs (FoxPro, Microsoft Corp)
including error, range and consistency check programs.
Fever was defined as history of a rise in body temperature
as recalled by the patient/caregiver or presence of axillary
temperature ≥37.5°C on presentation. Only one blood
culture was performed (on enrolment). Bacterial isolates
were classified as Gram-negative (including Salmonellae)
or Gram-positive. Malaria was defined as fever with the
presence of asexual malaria parasites on the blood film,
classified as P. falciparum, P. vivax, Plasmodium malariae
or Plasmodium ovale. Co-infection was defined as the
presence of bacteraemia and malaria.
The one-year incidence (per 100,000 population) of
fever episodes, malaria, bacteraemia and co-infections
was estimated using the number of such cases residing
in the referral population as the numerator and the
age-specific population from a study census as the
denominator. The incidence of P. vivax malaria and
typhoid fever have been previously reported [17], but
not of other bacteraemia and co-infections. The potential
association between the two binary variables, P. vivax
parasitaemia and bacteraemia on presentation for treat-
ment, was assessed using the Chi square test. Data analysis
was performed using Stata software, version 11.0. Statistical
significance was designated at p value <0.05.
Ethics
Written informed consent was obtained from each patient
or his/her parent or guardian prior to participation. The
Health Ministry Screening Committee of the Government
of India, the Institutional Review Board of the International
Vaccine Institute (Seoul, Korea) and the Secretariat
Committee for Research Involving Human Subjects,
World Health Organization (Geneva, Switzerland) approved
the study. The confidentiality of information collected from
study participants, including those derived from clinical
specimens was ensured during and after the conduct of the
study. All participant data were computerized using
password protection and all hard copy records were
kept at a secure place and available only to authorized
study personnel for research purposes.
Results
During the one-year study period, 3,371 (1,234 who were
2 months to 14 years of age) were enrolled and included
in the analysis (Table 1). Malaria parasites were detected
in the blood of 93/3,371 (2.8%) participants. Of the malaria
cases, 89/93 (95.7%) were P. vivax, 2 (2.2%) P. falciparum,
one (1.1%) P. malariae and one (1.1%) unspecified. Bacter-
aemia was detected in 256/3,371 (7.6%) participants. Of the
Table 1 Number (incidence per 100,000 population) of




Population denominator 60,452 15,980
No (%) participants enrolled 3,371 (5.6) 1,234 (7.7)
Mean age of participants 24.7 7.7
No (%) female participants 1,641 (48.7) 591 (47.9)
Number (incidence per 100,000 population) of:
Malaria 93 (154) 21 (131)
Bacteraemia 256 (423) 114 (713)
Gram-positive bacteraemia 32 (53) 4 (25)
Gram-negative bacteraemia 223 (369) 109 (682)
Typhoid fever 95 (157) 57 (357)
Other Salmonellosis
(63 S. Paratyphi A and 1 other)
64 (106) 31 (194)
Number (incidence per 100,000 population) of co-infections:
Malaria & bacteraemia 6 (10) 2 (13)
Falciparum malaria & bacteraemia 0 (0) 0 (0)
Vivax malaria & bacteraemia 6 (10) 2 (13)
Malaria & Gram-positive bacteraemia 1 (2) 0 (0)
Malaria & Gram-negative bacteraemia 5 (8) 2 (13)
Malaria & typhoid fever 1 (2) 1 (6)
Malaria & paratyphoid fever 1 (2) 0 (0)
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cluding S. Typhi (95 or 42.6%), S. Paratyphi A (63 or 28.3%)
and other Salmonellae (1 or 0.4%). Of the 89 vivax malaria
cases 6 (6.7% [95%CI: 3.1-13.9%]) had concomitant bacter-
aemia but similarly, 250/3278 (7.6% [95% CI: 6.7-8.6%]) of
the non-malarious cases were also bacteraemia (p=0.76).
There were 154 malaria and 423 bacteraemia episodes
per 100,000 population (131 and 713 in children) per
year (Table 1). Malaria and bacteraemia co-infections
occurred at 10 per 100,000 population (13 in children)
per year. Among the malaria-bacteraemia co-infections,
all were vivax malaria and 5/6 (83%) bacteria isolated
were Gram-negative (one S. Typhi, one S. Paratyphi A,
three other Gram-negative). There was one vivax mal-
aria and two typhoid fever cases who were hospitalized.
None of the patients with concomitant malaria and bac-
teraemia were hospitalized. There were no deaths
among the enrolled participants.
Discussion
In this Indian study site, a high proportion (6.7%) of vivax
malaria cases presenting for treatment had concomitant
bacteraemia. With 7.6% of non-malarious cases also bacter-
aemic, it could not be demonstrated that P. vivax infection
increases the risk of bacteraemia. Nevertheless, in areas likeKolkata, with a high incidence of both vivax malaria and
bacteraemia, co-infections are common.
The high frequency of P. vivax-bacteraemia co-infection
in this Indian site is notable because a number of series
from across this region have reported P. vivax infection
with severe sepsis-like syndromes [14,16]. Bacterial
co-infections could contribute to severe sepsis-like
presentations reported with P. vivax parasitaemia [10-16].
In falciparum malaria, bacteraemia, malnutrition and HIV
infection are biologically associated with severe disease
and an increased risk of death, rather than just being alter-
native diagnoses in coincidentally parasitized patients [19].
Similar relationships are plausible in vivax malaria where
severe disease may arise from P. vivax infection, bacterial
infection, or an additive or synergistic combination of both,
often with other comorbidities [16]. Hypnozoite activation
by significant systemic illness leading to vivax relapse has
also been proposed [20].
The study has several limitations. The confidence
interval for the 6.7% frequency of P. vivax-bacteraemia
co-infection is wide (3.1-13.9%); an increased risk of bac-
teraemia from P. vivax cannot be excluded. Considering
the insensitivity of blood cultures and widespread commu-
nity antibiotic usage, the frequency of bacteraemia and
bacteremia-P. vivax coinfection may be higher. Second,
since both malaria and bacteraemia were diagnosed and
treated at the same time (on presentation), only the rates of
concurrent vivax malaria and bacteraemia and a potential
association between both could be assessed and not
whether the former predisposes to the latter or vice versa.
And third, since majority of cases were captured in the
community and treated early, cases with severe manifesta-
tions were uncommon with only three patients hospital-
ized. Despite these limitations, this study provides the
largest and best available population-based dataset on the
relationship between P. vivax infection and bacteraemia.
The relationship between P. vivax malaria and bacter-
aemia is important to understand. P. vivax is a major
cause of morbidity and mortality and is estimated to
comprise around 40% of the world’s malaria burden [21].
As current malaria control and elimination programmes
disproportionately reduce the incidence of P. falciparum,
the global fraction of malaria due to P. vivax is expected
to rise. Whether P. vivax increases the risk for bacter-
aemia, the extent to which concurrent bacterial infection
contributes to manifestations and outcomes of severe
disease in P. vivax infection and whether systemic
bacterial infections increase vivax relapses all require
further elucidation. Multi-country, hospital-based studies
with systematic, quality-assured pre-antibiotic blood
and other sterile-site cultures in vivax malaria patients,
especially those with severe manifestations, are needed,
as well as follow-up studies of bacteraemic patients to
evaluate the risk of vivax relapse.
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In a region with a high risk of bacterial infection, con-
comitant bacteraemia in P. vivax infection is common.
Severe sepsis-like syndromes occurring in association with
P. vivax infection require blood cultures and consideration
of empiric broad-spectrum antimicrobial treatment.
Further studies are needed to understand the interaction
between vivax malaria and bacteraemia.
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